Skip to the page

Data / Drug companies / Asclemed USA Inc.

Asclemed USA Inc.: 116 products in the FDA NDC directory, labeler code 87063

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Asclemed USA Inc. (labeler code 87063) lists 116 products in the FDA National Drug Code Directory, covering 49 finished drugs by generic name. By type: 111 prescription drugs, 4 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on July 1, 2026.

The request: Watch Asclemed USA Inc. (FDA labeler code 87063): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
87063
Products in commercial distribution
116
Packages
553
Finished drugs by generic name
49
Prescription products
111
Over the counter products
4
Controlled substance products
Schedule II 9, Schedule III 1, Schedule IV 9
Flagged as original packager
1 of 1 products that carry the flag
Started marketing in the last 12 months
5
Products with a marketing end date set
1
Earliest marketing start
July 15, 1975
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)10287.9%
Authorized generics (NDA)43.4%
Other unapproved drugs43.4%
Over the counter monograph drugs32.6%
New drug applications (NDA)21.7%
Biologics (BLA)10.9%

Products by type

TypeProductsShare
Prescription drugs11195.7%
Over the counter drugs43.4%
Vaccines10.9%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Tablet7362.9%
Tablet, film coated1311.2%
Capsule65.2%
Ointment32.6%
Capsule, delayed release32.6%
Cream21.7%
Injection, solution21.7%
Solution21.7%
Patch21.7%
Injection21.7%
Gel21.7%
Injection, suspension21.7%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Flucelvax87063-299Injection, suspensionBiologics (BLA)July 1, 2026
Terocin87063-195PatchOver the counter monograph drugsMay 5, 2026
New Terocin87063-194LotionOver the counter monograph drugsMay 5, 2026
Marvona-25 SUIK87063-079Injection, solutionOther unapproved drugsJanuary 24, 2026
Lidothol ES87063-323SystemOther unapproved drugsJanuary 6, 2026
Methocarbamol87063-135TabletGeneric drugs (ANDA)May 22, 2025
Lidothol87063-218GelOther unapproved drugsMarch 27, 2025
Xiclofen87063-056OintmentOther unapproved drugsFebruary 7, 2025
Metoprolol tartrate87063-188TabletGeneric drugs (ANDA)July 26, 2024
Metoprolol tartrate87063-187TabletGeneric drugs (ANDA)July 26, 2024
Metoprolol tartrate87063-186TabletGeneric drugs (ANDA)July 26, 2024
Metoprolol tartrate87063-185TabletGeneric drugs (ANDA)July 26, 2024
Metoprolol tartrate87063-184TabletGeneric drugs (ANDA)July 26, 2024
Amoxicillin87063-058For suspensionAuthorized generics (NDA)April 1, 2024
Diclofenac Sodium87063-223SolutionGeneric drugs (ANDA)February 19, 2024
Levetiracetam87063-193TabletGeneric drugs (ANDA)May 1, 2023
Levetiracetam87063-192TabletGeneric drugs (ANDA)May 1, 2023
Levetiracetam87063-191TabletGeneric drugs (ANDA)May 1, 2023
Levetiracetam87063-190TabletGeneric drugs (ANDA)May 1, 2023
Ramelteon87063-189TabletGeneric drugs (ANDA)May 1, 2023
Valacyclovir87063-350TabletGeneric drugs (ANDA)February 14, 2023
Valacyclovir87063-349TabletGeneric drugs (ANDA)February 14, 2023
Methocarbamol87063-040Tablet, film coatedGeneric drugs (ANDA)February 9, 2023
Cevimeline hydrochloride87063-324CapsuleNew drug applications (NDA)January 3, 2023
Ropinirole87063-201Tablet, film coatedGeneric drugs (ANDA)September 15, 2022

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.